SV2009003275A - Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa - Google Patents

Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa

Info

Publication number
SV2009003275A
SV2009003275A SV2009003275A SV2009003275A SV2009003275A SV 2009003275 A SV2009003275 A SV 2009003275A SV 2009003275 A SV2009003275 A SV 2009003275A SV 2009003275 A SV2009003275 A SV 2009003275A SV 2009003275 A SV2009003275 A SV 2009003275A
Authority
SV
El Salvador
Prior art keywords
coenzima
estearoil
desaturasa
azacicloalcans
delta
Prior art date
Application number
SV2009003275A
Other languages
English (en)
Inventor
Sing Lee Chun
Nicolas Lachance
Jean-Philippe Leclerc
Yeeman K Ramtohul
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of SV2009003275A publication Critical patent/SV2009003275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LOS DERIVADOS DE AZACICLOALCANOS DE LA FORMULA ESTRUCTURAL I SON INHIBIDORES SELECTIVOS DE ESTEAROIL-COENZIMA A DELTA-9 DESATURASA (SCD1) CON RESPECTO A OTRAS ESTEAROIL-COENZIMA A DESATURASAS CONOCIDAS. LOS COMPUESTOS DE LA PRESENTE INVENCIÓN SON DE UTILIDAD PARA LA PREVENCIÓN Y TRATAMIENTO DE AFECCIONES RELACIONADAS CON LA SÍNTESIS Y METABOLISMO ANORMALES DE LÍPIDOS, INCLUIDAS ENFERMEDADES CARDIOVASCULARES, TALES COMO ATEROSCLEROSIS; OBESIDAD; DIABETES; ENFERMEDAD NEUROLÓGICA; SÍNDROME METABÓLICO; RESISTENCIA A INSULINA; Y ESTEATOSIS HEPÁTICA: (VER FORMULA)
SV2009003275A 2006-12-01 2009-05-27 Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa SV2009003275A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87221606P 2006-12-01 2006-12-01
US89890007P 2007-02-01 2007-02-01

Publications (1)

Publication Number Publication Date
SV2009003275A true SV2009003275A (es) 2009-11-18

Family

ID=39467388

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003275A SV2009003275A (es) 2006-12-01 2009-05-27 Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa

Country Status (24)

Country Link
US (1) US8063224B2 (es)
EP (1) EP2099793B1 (es)
JP (1) JP5050061B2 (es)
KR (1) KR20090086623A (es)
AR (1) AR064026A1 (es)
AT (1) ATE543816T1 (es)
AU (1) AU2007327276B2 (es)
BR (1) BRPI0719702A2 (es)
CA (1) CA2670703C (es)
CL (1) CL2007003440A1 (es)
CO (1) CO6190521A2 (es)
CR (1) CR10858A (es)
EA (1) EA200970524A1 (es)
EC (1) ECSP099375A (es)
GT (1) GT200900144A (es)
IL (1) IL198824A0 (es)
MA (1) MA31017B1 (es)
MX (1) MX2009005713A (es)
NO (1) NO20092469L (es)
PE (1) PE20081199A1 (es)
SV (1) SV2009003275A (es)
TN (1) TN2009000212A1 (es)
TW (1) TW200826936A (es)
WO (1) WO2008064474A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987001B2 (en) * 2000-02-24 2006-01-17 Xenon Pharmaceuticals Inc. Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
CA2651700A1 (en) * 2006-05-22 2007-11-29 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007260527A1 (en) * 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
JP2009539885A (ja) 2006-06-13 2009-11-19 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体
WO2008017161A1 (en) * 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) * 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
US20100120784A1 (en) * 2007-04-20 2010-05-13 Lachance Nicolas Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2008253512A1 (en) * 2007-05-23 2008-11-27 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2008157844A1 (en) 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
NZ583346A (en) * 2007-07-19 2012-02-24 Takeda Pharmaceutical Solid preparation comprising alogliptin and metformin hydrochloride
JP2010533658A (ja) * 2007-07-20 2010-10-28 メルク フロスト カナダ リミテツド ステアロイル補酵素ａデルタ−９デサチュラーゼ阻害剤としての二環性へテロ芳香族化合物
EP2334666A1 (en) * 2008-09-08 2011-06-22 Merck Canada Inc. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ES2545864T3 (es) * 2009-02-17 2015-09-16 Merck Canada Inc. Nuevos compuestos espiránicos útiles como inhibidores de la estearoil-coenzima A delta-9 desaturasa
US20110301143A1 (en) * 2009-02-23 2011-12-08 Elise Isabel Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2010108268A1 (en) * 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
KR20130100903A (ko) 2010-04-28 2013-09-12 바이엘 크롭사이언스 아게 살진균제로서의 케토헤테로아릴피페리딘 및 케토헤테로아릴피페라진 유도체
AU2012210489B2 (en) * 2011-01-28 2017-01-12 Immunic Ag IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013062882A1 (en) * 2011-10-26 2013-05-02 Merck Canada Inc. Scd inhibitors for the treatment of hcv
US9233102B2 (en) 2012-03-07 2016-01-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN104768549A (zh) 2012-05-22 2015-07-08 耶路撒冷希伯来大学的益生研究开发有限公司 未分化细胞的选择性抑制剂
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2018205275B2 (en) * 2017-01-06 2024-05-02 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1595923A1 (de) * 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung
PT876366E (pt) 1996-01-15 2002-01-30 Janssen Pharmaceutica Nv Piridazinaminas inibidoras da angiogenese
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7514436B2 (en) 2003-07-30 2009-04-07 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
WO2006034440A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
TW200626572A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AR051294A1 (es) 2004-09-20 2007-01-03 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
BRPI0515483A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
EP1814551A2 (en) 2004-09-20 2007-08-08 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
WO2006125181A2 (en) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Piperidine derivatives and their use as stearoyl-coa desaturase modulators
WO2006130986A1 (en) 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20090118296A1 (en) 2005-07-20 2009-05-07 Merck Frosst Canada Ltd. Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase
US20090054483A1 (en) 2005-10-05 2009-02-26 Yves Ducharme Substituted Quinolines as Inhibitors of Leukotriene Biosynthesis
JP2009515839A (ja) 2005-11-15 2009-04-16 メルク フロスト カナダ リミテツド ステアロイル−ＣｏＡデルタ−９デサチュラーゼ阻害剤としてのアザシクロヘキサン誘導体
WO2007071023A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2651700A1 (en) 2006-05-22 2007-11-29 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007260527A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
JP2009539885A (ja) 2006-06-13 2009-11-19 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体
WO2008017161A1 (en) 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2664849A1 (en) 2006-10-20 2008-04-24 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa

Also Published As

Publication number Publication date
EP2099793A1 (en) 2009-09-16
GT200900144A (es) 2011-06-23
JP5050061B2 (ja) 2012-10-17
ATE543816T1 (de) 2012-02-15
CO6190521A2 (es) 2010-08-19
MX2009005713A (es) 2009-06-08
TN2009000212A1 (en) 2010-10-18
JP2010510993A (ja) 2010-04-08
ECSP099375A (es) 2009-07-31
NO20092469L (no) 2009-08-27
MA31017B1 (fr) 2009-12-01
CL2007003440A1 (es) 2008-04-04
KR20090086623A (ko) 2009-08-13
AU2007327276B2 (en) 2011-06-09
CA2670703A1 (en) 2008-06-05
EA200970524A1 (ru) 2009-12-30
WO2008064474A1 (en) 2008-06-05
EP2099793A4 (en) 2010-12-29
TW200826936A (en) 2008-07-01
IL198824A0 (en) 2010-02-17
AU2007327276A1 (en) 2008-06-05
EP2099793B1 (en) 2012-02-01
CA2670703C (en) 2012-05-15
BRPI0719702A2 (pt) 2013-12-17
US20080132542A1 (en) 2008-06-05
US8063224B2 (en) 2011-11-22
AR064026A1 (es) 2009-03-04
CR10858A (es) 2009-06-25
PE20081199A1 (es) 2008-10-19

Similar Documents

Publication Publication Date Title
SV2009003275A (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
MX2010012961A (es) Imidazopiridina y analogos relacionados como moduladores de sirtuina.
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
MX2011006084A (es) Isoindolinona y analogos relacionados como moduladores de sirtuina.
HRP20090235B1 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d
EP2342188A4 (en) CHROMENONE ANALOGUES AS MODULATORS OF SIRTUIN
MX2011009213A (es) Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
CR20110255A (es) Nuevos compuestos 578
UA104447C2 (uk) Тіазолопіридинові сполуки, що модулюють сиртуїн
MX2011006475A (es) Ftalazinona y analogos relacionados como moduladores de sirtuina.
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
BR112012033402A2 (pt) moduladores de canais de íons conforme os compostos heterocíclicos fundidos
BR112012021771A2 (pt) métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2.
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
WO2011056985A3 (en) Substituted heterocyclic compounds
WO2009121939A3 (en) C-aryl glycoside compounds for the treatment of diabetes and obesity
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
EA201000751A1 (ru) Производные 7-азаиндола в качестве селективных ингибиторов 11-бэта-гидроксистероида дегидрогеназа 1 типа